PharmiWeb Today Story
- Acquisition to support the global execution of BioNTech’s oncology strategy and provide full global rights to BNT327/PM8002, an investigational PD-L1 x VEGF-A bispecific antibody, with potential to replace current checkpoint inhibitor standard of care treatments for solid tumors
- With the acquisition of Biotheus, BioNTech aims to further strengthen its capabilities to develop, manufacture and commercialize next-generation bispecific antibodies and novel treatment combinations
- BioNTech and Biotheus plan to initiate multiple registrational trials with BNT327/PM8002 in late 2024 and 2025; further clinical trials evaluating BNT327/PM8002 as combination therapies are planned to start in 2024 and 2025
- BioNTech to pay $800 million to acquire 100 percent of the issued share capital and up to $150 million in potential milestone payments
- Additional details will be shared at BioNTech’s Innovation Series R&D Day event on 14 November 2024
MAINZ, Germany, November 13, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Biotheus (“Biotheus”) today announced the signing of a definitive agreement for the acquisition of Biotheus, a clinical-stage biotechnology company dedicated to the discovery and development of novel antibodies to address unmet medical needs of patients with oncological or inflammatory diseases.
With the acquisition, BioNTech will obtain full global rights to the late-stage clinical asset BNT327/PM8002, an investigational bispecific antibody targeting PD-L1 and VEGF-A. The transaction is part of BioNTech’s oncology strateg…
Articles
How to Actually Network at an Industry Event
28-Oct-2024
How AI is Impacting Graduate Recruitment
23-Oct-2024
Trick or Treat: Spotting Red Flags in Job Offers
15-Oct-2024
Featured Events
-
1st International Conference “WE! are the Clinical…
18-Sep-2021 - 18-Sep-2021 -
Pharma USA 2022
16-Mar-2022 - 17-Mar-2022 -
Reuters Events: Pharma 2022
11-Oct-2022 - 13-Oct-2022 -
PM Society: Measuring Patient Engagement: Opening…
12-Oct-2022 - 12-Oct-2022 -
Reuters Events: Pharma USA 2023
28-Mar-2023 - 29-Mar-2023 -
Global Biomanufacturing Summit
25-May-2023 - 26-May-2023
News
-
Enalare Therapeutics is Granted a New Patent for E…
14-Nov-2024 -
In full bloom: WEECO Pharma boosts SYNBIOTIC's sal…
14-Nov-2024 -
Tonix Pharmaceuticals Targets Rapid Migraine Relie…
14-Nov-2024 -
Interactive Strength Inc. (Nasdaq:TRNR) Reports Th…
14-Nov-2024 -
Neuraxpharm reports another year of sustained grow…
14-Nov-2024 -
Vivet Therapeutics to Present Key Findings on its…
14-Nov-2024